Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck & Co., Inc
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Montelukast as a controller of atopic syndrome - MONTAS-study
To test if montelukast could be used as an easy systemic controller of various aspects of atopic syndrome (rhinitis, conjunctivitis, asthma, eczema, oral symptoms).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM)
1. To assess the effects of MK-0364 on body weight after 36 weeks of treatment. 2. To assess the effects of MK-0364 on hemoglobin A1c (HbA1c) after 36 weeks of treatment. 3. To assess the safety a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Ensayo clínico de fase IIa, multicéntrico, aleatorizado, controlado con placebo y con tratamiento activo, cruzado para estudiar la seguridad y la eficacia de MK-3577 en pacientes con diabetes mellitus de tipo 2 con control insuficiente de la glucemia. A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
To assess the 24-hour weighted mean glucose (WMG)-lowering efficacy, safety and tolerability of MK-3577
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
Evaluate the LDL-C-lowering effects and evaluate the HDL-C-raising effects of MK-0524B combination tablet versus coadministered MK-0524A and Simvastatin.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A
MAJ Il y a 5 ans
A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence
Evaluate efficacy of MK-0594 in maintaining absence of heavy alcohol drinking over Weeks 3-12 of a 12-week treatment period
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age
To demonstrate that at 1 month after the third dose of vaccine, either the modified process hepatitis B vaccine at 5 µg/0.5 mL or RECOMBIVAX HB™ will induce adequate seroprotection rates (SPR).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Objectives 1st extension: 1. To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. 2. To assess safet...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study of safety and efficacy of different doses of the study drug, MK-0854/Losartan Potassium, in pediatric patients with high blood pressure assigned to different groups randomly. Treatment is known to doctor and patient
(1) To define a dose-response relationship for losartan in hypertensive children aged 6 months to 6 years, after a 21-day open-label treatment period (response assessed by change from baseline in mean...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab in Subjects with Advanced Recurrent Ovarian Cancer
(1) To evaluate clinical anti-tumor activity of pembrolizumab monotherapy based on overall response rate (ORR) as assessed by CIV per RECIST 1.1 in Cohort A-All Comer group (2) To evaluate clinical...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Women with Osteoporosis
For Base Study: To assess the effect of L-001037536 3 mg weekly, 10 mg weekly, 25 mg weekly, and 50 mg weekly on lumbar spine BMD compared to placebo over 12 months. For 24 Months Extension: To ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
13
14
15
16
17
18
19
20
21
22
Suivant